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Abstract 
Introduction: MicroRNA-1258 (miR-1258) has been shown to play an anti-cancer role 
in a variety of cancers, but its relationship with papillary thyroid cancer (PTC) has not 
been reported. The emphasis of this research was to reveal the biological function of 
miR-1258 in PTC and its potential mechanisms. 
Material and methods: We measured miR-1258 expression in PTC cells and the 
transfection efficiency of miR-1258 mimic and miR-1258 inhibitor by quantitative real-
time PCR (qRT-PCR) assay. Cell Counting Kit-8 assay (CCK8) and Transwell 
experiments were conducted to examine the influences of altering miR-1258 expression 
on the viability, migration, and invasion of PTC cells. Bioinformatics prediction and 
dual-luciferase experiment were performed to verify the target gene of miR-1258. 
Finally, we carried out a rescue assay to verify whether the regulation of miR-1258 on 
the biological behaviour of PTC cells needs to be achieved by regulating TMPRSS4. 
Results: The outcomes revealed that miR-1258 was lowly expressed in PTC cell lines 
and miR-1258 showed the lowest expression in KTC-1 and the highest expression in B-
CPAP among all tested PTC cell lines. Overexpression of miR-1258 inhibited KTC-1 
cell viability and ability to migrate and invade, whereas inhibition of miR-1258 in B-
CPAP cells has the opposite effect. Furthermore, we affirmed that miR-1258 can 
directly target TMPRSS4, and miR-1258 can reduce the biological malignant behaviour 
of PTC cells via regulation of TMPRSS4. 
Conclusion: Taken together, our research raised the possibility that miR-1258 was an 
anti-oncogene, which exerts its anti-cancer function by targeting TMPRSS4. Hence, it 
may be possible to treat PTC by targeting the MIR-1258/TMPRSS4 axis in the future. 
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Introduction 
Papillary thyroid cancer (PTC), as the most common subtype of thyroid cancer, has the 
characteristics of high cure rate and long-term survival rate (> 95%) [1–3]. In some 
patients with poor prognosis, recurrence and metastasis are the direct factors leading to 
death [4, 5]. Although PTC is more common in female patients, the mortality rate of 
male patients is higher [6, 7]. To date, most patients with PTC can be cured by surgery, 
but owing to the increasing incidence of PTC [8] and the high mortality rate of patients 
with recurrence and metastasis, a useful target of the diagnosis and therapy of PTC still 
need to be studied and developed. 
MicroRNA (miRNA), as an endogenous small RNA in the non-coding region of the 
genome [9, 10], can regulate more than 30% of human genes and contributes to the 
regulation of various major diseases in humans [11]. Extensive research has reported 
the role of miRNAs in PTC; for example, up-regulation of miR-222 expression in PTC 
was associated with clinical risk stratification [12]. MiR-23a was down-regulated in 
PTC and participates in the regulation of PTC by targeting CCNG1 [13]. MiR-96-5p 
induced the invasion and migration of PTC cells by silencing the expression of 
CCDC67, thus accelerating the development of PTC [14]. In contrast, miR-506 can 
significantly reduce the migration and invasion ability of PTC cells [15]. MicroRNA-
1258 (miR-1258), as one of the miRNAs, has been reported to participate in regulating 
the process of carcinoma and plays a tumour suppressive role in many cancers, such as 
NSCLC(17), ovarian cancer [18], osteosarcoma [19], oral squamous cell carcinoma 
[20], colorectal cancer [21], breast cancer [22], etc. Nevertheless, no previous research 
has been performed on the relationship between miR-1258 and PTC. 
On the basis of existing literature data, we carried out studies in an effort to investigate 
the role of miR-1258 in the viability, migration, and invasion of PTC cells, and to study 
its potential target genes. It was expected to provide a potentially useful strategy for the 
diagnosis and therapy of PTC. 
 
Materials and method 
Data collection 
In this study, we downloaded data from the The Cancer Genome Atlas (TCGA) 
database (https:// www.cancer.gov/about-nci/organization/ccg/research /structural-
genomics/tcga) to analyse the difference of the expression of miR-1258 in PTC cells 
and normal cells. Similarly, the data of 510 tumour samples and 58 healthy controls 
were downloaded from the TCGA database and used to analyse differential expression 
of transmembrane protease serine 4 (TMPRSS4). 
 
Cell culture 
Human B-CPAP, BHT101, and KTC-1 PTC cell lines (Shanghai Cell Bank of Chinese 
Academy of Medical Sciences) and normal thyroid epithelial cell Nthy-ori 3-1 
(European Collection of Cell Culture, Salisbury, UK) were routinely cultured in RPMI-
1640 medium containing 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin 
at 37ºC with 5% CO2. 
 
Cell transfection 
MiR-1258 mimic/inhibitor and corresponding NC were obtained from Shanghai 
GenePharma Co., Ltd. (Shanghai, China), and pcDNA3.1-TMPRSS4, si-TMPRSS4, si-
con were compounded by Shanghai GenePharma Co., Ltd. (Shanghai, China). The 
conventionally cultured cells were seeded in a six-well plate before transfection for 24 
h. When the cell fusion degree achieved 70–90%, the culture medium was swapped to 
antibiotic-free and serum-free medium, and then transfected using Lipofectamine 2000 
after 2 h. The transfection was carried out according to the instructions of the 
Lipofectamine 2000 transfection kit. After 48 hours, the transfection was observed, and 
the cells were collected for further assays. 
 
Quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted by RNeasy Mini Kit (Qiage, Dusseldorf, Germany) according 
to the manufacturer’s instructions. After that, M-MLV (Clontech, Palo Alto, USA) and 
miScript PCR reverse transcription kit (Qiagen, Dusseldorf, Germany) were used for 
reverse transcription. Then, using the qRT-PCR kit to test the expression level of miR-
1258/TMPRSS4, GAPDH and U6 were used as the internal reference genes. The qRT-
PCR reaction was carried out as follows: 95ºC for 5 min, 95ºC for 5 s, and 60ºC for 30 
s; 40 cycles, using the 2-△△Ct method to calculate the relative quantities. The specific 
primer sequences were: 
— MiR-1258:  
F: 5’-GTTAGGATTAGGTCGTGG-3’ 
R: 5’-GAACATGTCTGCGTATCTC-3’ 






— GAPDH:  
F: 5’-TAG ATGACACCCGTCCCTGA-3’ 
R: 5’-ACCTCCACCTGTCCTTAGTG-3’ 
 
Western blotting assay 
Six-well plates with transfected cells were placed on ice, and protein was extracted by 
RIPA lysis buffer with protease inhibitor. Then a BCA protein quantitative kit was used 
to measure the protein content in the samples. About 20 μg of the above protein was 
conducted to SDS-PAGE electrophoresis, followed by transferral of the separated 
protein sample to a PVDF membrane. After adding Western Sealing Solution (5% 
skimmed milk powder) to seal for 1 h, incubation of the membrane overnight at 4ºC 
with primary antibody, followed by rinsing the incubated membrane three times with 
TBST for five minutes each time was carried out. Then the secondary antibody was 
added to the membrane and incubated for 1 h at room temperature. After rinsing with 
TBST for 3  5 min, the images were developed with an ECL Western blotting kit 
(Thermo Fisher Scientific, Inc.). Using Quantity One software to analyse the greyscale 
value of protein bands, GAPDH was used as the internal reference gene.  
 
Cell counting kit-8 (CCK8) assay 
The transfected cells were prepared into cell suspension and inoculated on a 96-well 
plate at a density of 1  105 cells/well, followed by conventional culturing in a 5% CO2 
incubator. OD values at 450 nm wavelength of each well were measured using a 
microplate reader at 0 h, 24 h, 48 h, and 72 h. Notably, 10 μl of CCK8 solution was 
added to each well 2 h before detection. 
 
Transwell assay 
40μl of Matrigel Matrix glue was added to the upper chamber of the Transwell chamber 
and incubated overnight at 37ºC to make the Matrigel gelatinous. The migration assay 
did not require gluing treatment. After digestion, serum-free culture medium was used 
to prepare the cell suspension. The cell suspension was added to the upper chamber at 
the density of 1  105 cells, and 500 μl of complete culture medium was added to the 
lower chamber. Then the chamber was cultured at 37ºC for 24 h in a 5% CO2 incubator. 
Afterwards, the chamber was removed and the remaining cells were wiped from the 
upper chamber with a cotton swab. The cells in the lower chamber were fixed with 4% 
paraformaldehyde for 15 minutes and stained with 0.1% crystal violet for three minutes. 
Finally, five visual fields were randomly selected under an optical microscope to 
observe and count the cells. 
 
Bioinformatics prediction 
The target gene of miR-1258 was predicted by the target gene prediction and analysis 
websites miRbase (http://www.mirbase.org/) and TargetScan 
(http://www.targetscan.org/). 
 
Dual-luciferase reporter assay 
In order to verify whether miR-1258 can directly target TMPRSS4, dual-luciferase 
reporter assay was performed. The wild type and mutant type 3’UTR of TMPRSS4 were 
cloned into pmirGLO luciferase vector to construct a luciferase expression plasmid 
TMPRSS4-WT and TMPRSS4-MUT, respectively, and they were co-transfected into 
HEK-293T cells with miR-1258 mimic or miR-1258 mimic NC. Lipofectamine 2000 
was used for transfection according to the instructions. Luciferase activity was detected 
after 24 h. 
 
Statistical analysis 
The experimental data were analysed by SPSS22.0 statistical analysis software. T-test 
was used to compare the differences between the two groups, and one-way ANOVA 
analysis and post-test of Tukey were used to compare the differences between three or 




MiR-1258 was lowly expressed in PTC cell lines 
Firstly, the bioinformatics analysis results in Figure 1A showed that miR-1258 
expression was markedly lower in PTC tumour tissues than in normal tissues (p < 
0.0001). Subsequently, we confirmed this difference in PTC cell lines by qRT-PCR 
assay. Figure 1B indicated that miR-1258 expression was markedly lower in PTC cell 
lines B-CPAP, BHT101, and KTC-1 than that in normal healthy cell Nthy-ori 3-1 (p < 
0.01). Interestingly, we also found that miR-1258 showed unequal expression in 
different PTC cell lines, with the lowest expression in KTC-1 and the highest expression 
in B-CPAP. 
 
The effect of miR-1258 inhibitor/mimic transfection on the expression of miR-1258 
in PTC cells 
To detect the function of miR-1258 inhibitor/mimic, we selected KTC-1 for over-
expression assay and B-CPAP for knockdown assay. KTC-1 was transfected with miR-
1258 mimic and miR-1258 mimic NC, simultaneously B-CPAP was transfected with 
miR-1258 inhibitor and miR-1258 inhibitor NC. Cells that were treated with 
transfection reagent were considered as controls. Then the expression of miR-1258 in 
KTC-1/ B-CPAP cells after transfection was detected by qRT-PCR. Fig.1C-D shows 
that miR-1258 expression was markedly increased in KTC-1 cells transfected with miR-
1258 mimic compared with that in KTC-1 cells transfected with miR-1258 mimic NC 
and in controls (p < 0.01), while the expression of miR-1258 was obviously reduced in 
CPAP cells transfected with miR-1258 inhibitor compared to that in B-CPAP cells 
transfected with miR-1258 inhibitor NC and in controls (p < 0.01). These results 
illustrated a successful transfection and a high transfection efficiency. 
 
The influence of altering the miR-1258 expression level on the biological behaviour 
of PTC cells 
To verify whether miR-1258 plays a biological function in PTC cells, CCK8 and 
Transwell experiments were set up to detect cell viability, migration, and invasion. It 
can be seen from Figure 2A that the cell viability of KTC-1 cells transfected with miR-
1258 mimic declined more than that in the control group (p < 0.01), whereas it can be 
seen from Fig. 2D that the cell viability showed a marked increase after inhibition of 
miR-1258 expression in B-CPAP cells (p < 0.01). The results obtained from the 
Transwell assay indicated that after overexpression of miR-1258 in KTC-1 cells, the 
number of migrating and invading cells through the Transwell membrane was markedly 
reduced compared to that in the control group (Fig. 2 BC, p < 0.01), whereas 
suppression of miR-1258 in B-CPAP cells showed the opposite effect (Fig. 2EF, p < 
0.01). Overall, these results demonstrate that overexpression of miR-1258 can inhibit 
the cell viability, migration, and invasion in PTC, and thus miR-1258 may be a tumour 
suppressor gene in PTC. 
 
MiR-1258 directly targets TMPRSS4 
To explore the mechanism of regulation of PTC by miR-1258 we used a target gene 
prediction website to predict and analyse the target of miR-1258. Bioinformatics 
analysis indicated that TMPRSS4 was more highly expressed in PTC cells than in 
normal cells (Fig. 3A, p < 0.0001), and it may be a potential target gene for miR-1258, 
which has predicted target sites for miR-1258 in the 3'-UTR region (Fig. 3B). To 
validate further whether TMPRSS4 is a direct target gene of miR-1258, TMPRSS4-WT 
or TMPRSS4-MUT and miR-1258 mimic or miR-1258 mimic NC were co-transfected 
into HEK 293T cells to determine the cell luciferase activity. From Figure 3C we can 
see that miR-1258 mimic significantly reduced the luciferase activity of wild-type 
compared to the negative control group (p < 0.01), whereas the luciferase activity of 
the mutant did not change markedly compared with the control group.  
Subsequently, Western blot assay was carried out to test the influence of 
overexpression/suppression of miR-1258 on TMPRSS4 protein levels. The results from 
Figure 3DE revealed that the level of TMPRSS4 protein in KCT-1 cells transfected with 
miR-1258 mimic decreased significantly compared to that in the control group (p < 
0.01), while the level of TMPRSS4 was markedly higher in KCT-1 cells co-transfected 
with mimic and pcDNA3.1-TMPRSS4 compared to that in the miR-1258 mimic group 
(p < 0.01). Simultaneously, it can be concluded from Figure 3EF that inhibition of miR-
1258 expression in B-CPAP cells can significantly increase the level of TMPRSS4 
protein compared to the control group (p < 0.01), whereas TMPRSS4 protein level in 
B-CPAP cells co-transfected with miR-1258 inhibitor and si-TMPRSS4 was reduced 
significantly compared to those in the inhibitor group. Overall, these results illustrate 
that miR-1258 can directly target the TMPRSS4 gene and negatively regulate its 
expression. 
Regulation of the miR-1258/TMPRSS4 axis on the phenotype of PTC 
To confirm whether miR-1258 regulates the biological behaviour of PTC cells by 
regulating TMPRSS4, a rescue experiment was performed. Firstly, KTC-1 cells were 
transfected with miR-1258 mimic or miR-1258 mimic plus pcDNA3.1-TMPRSS4, and 
B-CPAP cells were transfected with miR-1258 inhibitor or miR-1258 inhibitor plus si-
TMPRSS4, and negative control groups were set respectively. The viability, migration, 
and invasion of cells under different conditions were examined by CCK8 and Transwell 
experiments. As shown in Figure 4A–C, the cell viability, migration, and invasion were 
reduced significantly more in KTC-1 cells transfected with miR-1258 mimic than that 
in the controls (p < 0.01), whereas after overexpression of TMPRSS4 in the miR-1258 
mimic group, the cell viability and the number of migrating and invading cells were 
markedly elevated compared to those in the mimic group (p < 0.01). At the same time, 
down-regulation of miR-1258 expression in B-CPAP cells significantly increased cell 
viability, migration, and invasive ability, while knockdown of TMPRSS4 in the inhibitor 
group showed the opposite effect. This suggests that overexpression of TMPRSS4 can 
reverse the anti-cancer properties of miR-1258. Thence, miR-1258 can reduce the 
viability, migration, and invasion of PTC cells via regulating TMPRSS4. 
 
Discussion 
In this paper, we found for the first time that miR-1258 was lowly expressed in PTC 
cell lines. Subsequently, a series of experimental results showed that suppression of 
miR-1258 in PTC can improve cell viability, migration, and invasion, while 
overexpression of miR-1258 showed the opposite effect. Finally, we confirmed that 
miR-1258 could directly target TMPRSS4, and it promoted the biological behaviour of 
PTC cells via regulation of TMPRSS4. 
To date, a number of studies have revealed that miR-1258 has an imbalanced expression 
in various cancers. For example, down-regulated miR-1258 expression in osteosarcoma 
was related to unfavourable prognosis [19]. MiR-1258, as an anti-cancer gene, also 
plays a role in inhibiting the process of oral squamous cell carcinoma [20]. The anti-
cancer effect of miR-1258 in colorectal cancer was achieved by negative regulation of 
E2F8 [21]. MiR-1258 was a diagnostic and therapeutic marker of hepatocellular 
carcinoma [23], and also can be used as a downstream functional target to regulate the 
process of hepatocellular carcinoma [24]. Recently, Filippova EA et al. found that 
methylation of miR-1258 can be used as a predictor of ovarian cancer metastasis [18]. 
This paper first identified the low expression of MIR-1258 in PTC, and up-regulation 
of miR-1258 markedly reduced the viability, migration, and invasion of PTC cells, 
while suppression of miR-1258 showed the opposite effect. Taken together, we 
concluded that miR-1258 may has the tumour suppressor function of regulating the 
biological behaviour of PTC cells. 
In this paper, we identified that TMPRSS 4 might be a target gene of miR-1258 by using 
a target gene prediction website. Type II transmembrane serine proteases (TTSP) have 
been found to be dysfunctional in a variety of cancers, which can activate signalling 
pathways leading to cancer [25]. TMPRSS4, as a new member of TTSP, has been found 
to be highly expressed in many cancers, such as pancreatic cancer [26], gastric cancer 
[27], lung adenocarcinoma [28], hepatocellular carcinoma [29], and breast cancer [30]. 
In addition, Mahati et al. pointed out that up-regulation of TMPRSS4 expression can 
promote the occurrence and development of various biological behaviours of cancer 
cells [29]. Based on the bioinformatics analysis and experimental results, we verified 
that TMPRSS4 was the direct target gene of miR-1258, and up-regulation of TMPRSS4 
expression reduced the influence of miR-1258 to inhibit the viability, migration, and 
invasion in PTC cells, while knockdown of TMPRSS4 has the opposite effect. Hence, 
it is possible that miR-1258 plays an anti-cancer role by regulating TMPRSS4 in PTC, 
but the underlying mechanisms require further study. 
From this paper, we concluded that miR-1258 was lowly expressed in PTC, and 
overexpression of miR-1258 can inhibit cell viability, migration, and invasion, which 
raises the standpoint that miR-1258 is an anti-oncogene. Furthermore, we found that 
miR-1258 may play an anti-cancer role in PTC by regulating TMPRSS4, suggesting that 
the miR-1258/TMPRSS4 axis may be a potential biomarker and therapeutic target for 
the diagnosis and therapy of PTC. In the next step, we will further validate our 
experimental data through in vivo experiments. 
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Figure 1. miRNA expression level of miR-1258 in papillary thyroid cancer (PTC). A. 
MiR-1258 was lowly expressed in the tumour group (n = 514) and the normal group (n 
= 59) on the basis of data from TCGA (p < 0.0001). B. Through quantitative real-time 
PCR (qRT-PCR) experiment, the expression of miR-1258 was markedly reduced in PTC 
cell lines B-CPAP, BHT101, KTC-1 than that in normal healthy cell Nthy-ori 3-1 (**p 
< 0.01). C. The expression of miR-1258 in KTC-1 cells transfected with miR-1258 
mimic showed an obvious increase compared with that in KTC-1 cells transfected with 
mimic NC and that in controls (**p < 0.01). D. The expression of miR-1258 in B-CPAP 
cells transfected with miR-1258 inhibitor was significantly decreased compared with 






Figure 2. Influence of altering the expression of miR-1258 on the cell biological 
behaviour in KTC-1 and B-CPAP. A. Cell Counting Kit-8 (CCK8) assay results 
indicated that up-regulation of miR-1258 expression markedly declined the viability of 
KTC-1 cells compared to that in controls (**p < 0.01). B. Down-regulation of miR-1258 
expression markedly enhanced the viability of B-CPAP cells compared to that in 
controls (**p < 0.01). C, D. Transwell assay results illustrated that up-regulation of miR-
1258 obviously reduced the number of migrating and invading cells in KTC-1 
compared to that in controls (**p < 0.01). E, F. Inhibition of miR-1258 expression can 
improve the cell invasion and metastasis of B-CPAP cells compared to that in controls 




Figure 3. MiR-1258 directly targets TMPRSS4. A. Relative expression level of 
TMPRSS4 in normal cells (n = 58) and tumour cells (n = 510) was analysed on the basis 
of data from TCGA (p < 0.0001). B. Alignment of miR-1258 with TMPRSS4 sequences. 
C. The fluorescence intensity was markedly decreased in HEK 293T cells co-
transfected with TMPRSS4-WT and miR-1258 mimic (p < 0.01), while the fluorescence 
intensity of TMPRSS4-MUT and miR-1258 mimic co-transfected cells was almost 
unchanged. D, E. Overexpression of miR-1258 markedly decreased the level of 
TMPRSS4 protein compared with controls in KTC-1 cells (**p < 0.01), while the 
TMPRSS4 protein level was markedly increased in pcDNA 3.1-HAO2 and miR-1258 
mimic co-transfected cells compared to the miR-1293 mimic group (**p < 0.01). F, G. 
Inhibition of miR-1258 in B-CPAP cell can elevate the expression of TMPRSS4 (**p < 
0.01), whereas knockdown of TMPRSS4 in the miR-1258 inhibitor group, TMPRSS4 
protein level was markedly lower compared with that in the miR-1258 inhibitor group 
(**p < 0.01) 
 
  
Figure 4. The effect of the miR-1258/TMPRSS4 axis on the function of PTC. A–C. 
Overexpression of miR-1258 significantly reduced the viability, invasion, and 
metastasis of KTC-1 cells compared to that in the control group (**p < 0.01, ##p < 0.01), 
while the biological behaviour of KTC-1 cells co-transfected with pcDNA3.1-
TMPRSS4 and miR-1258 mimic was markedly elevated compared to that in the miR-
1293 mimic group. (**p < 0.01, ##p < 0.01). D–F. Suppression of miR-1293 markedly 
induced the viability, invasion, and metastasis of B-CPAP cells compared to those in 
the control group (**p < 0.01), while the biological behaviour of B-CPAP cells co-
transfected with si-TMPRSS4 and miR-1293 inhibitors was significant reduced 
compared to that in the miR-1293 inhibitor group. (**p < 0.01) 
 
